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Abbreviations Table: 
IB Incisional Biopsy 
PCNB Percutaneous Core Needle Biopsy 
INRG International Neuroblastoma Risk Group 
PSORC Pediatric Surgical Oncology Research Collaborative 
COG Children’s Oncology Group 
LOH Loss of Heterozygosity 
NPO Nil per Os 
PCA Patient Controlled Analgesia 
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Image-guided percutaneous core needle biopsy (PCNB) is increasingly utilized to diagnose 
solid tumors. The objective of this study is to determine whether PCNB is adequate for 
modern biologic characterization of neuroblastoma. 
Procedure 
A multi-institutional retrospective study was performed by the Pediatric Surgical Oncology 
Research Collaborative on children with neuroblastoma at 12 institutions over a 3-year 
period. Data collected included demographics, clinical details, biopsy technique, 
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complications, and adequacy of biopsies for cytogenetic markers utilized by the Children’s 
Oncology Group for risk stratification. 
Results 
243 children were identified with a diagnosis of neuroblastoma: 79 (32.5%) tumor excision at 
diagnosis, 94 (38.7%) open incisional biopsy (IB), and 70 (28.8%) PCNB. Compared to IB, 
there was no significant difference in ability to accurately obtain a primary diagnosis by 
PCNB (95.7% vs 98.9%, p = 0.314) or determine MYCN copy number (92.4% vs 97.8%, p = 
0.111). The yield for loss of heterozygosity and tumor ploidy was lower with PCNB versus 
IB (56.1% vs 90.9%, p<0.05; and 58.0% vs. 88.5%, p<0.05). Complications did not differ 
between groups (2.9 % vs 3.3%, p = 1.000), though the PCNB group had fewer blood 
transfusions and lower opioid usage. Efficacy of PCNB was improved for loss of 
heterozygosity when a pediatric pathologist evaluated the fresh specimen for adequacy. 
Conclusions 
PCNB is a less invasive alternative to open biopsy for primary diagnosis and MYCN 
oncogene status in patients with neuroblastoma. Our data suggests that PCNB could be 
optimized for complete genetic analysis by standardized protocols and real-time pathology 
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Introduction 
Neuroblastoma is the most common extracranial solid tumor in children, with 
approximately 700 new cases diagnosed each year in the United States.
1
 Tumor biologic and 
genetic characteristics are heterogeneous, and therapeutic decisions depend on appropriate 
tissue sampling and risk classification.
2
 MYCN amplification and segmental chromosomal 
alterations are important indicators that drive treatment decisions and determine overall 
disease risk. High-risk patients receive intense cytotoxic chemotherapy, while some patients 
with low-risk disease can be managed with observation alone. The optimal technique for 
tissue acquisition minimizes patient morbidity and obtains adequate tissue for complete 
biologic analysis and pretreatment assessment. Tissue biopsy has traditionally been achieved 
with open incisional biopsy (IB), however the use of image-guided percutaneous core needle 
biopsy (PCNB) is increasingly utilized for pediatric surgical patients. PCNB offers 
substantial advantages including lower procedural costs, fewer complications, and avoids the 
risks of open surgery.
3--5
 
The International Neuroblastoma Risk Group (INRG) Task Force developed 
guidelines for neuroblastoma risk stratification which include age, radiographic imaging 
factors, tumor stage, and tumor genetic profile.
2,6
 There is conflicting data regarding the 
efficacy of PCNB for cytogenetic analysis, relying primarily on single-institutional data. 
Several reports have demonstrated comparable accuracy between PCNB and IB, while others 
challenge the full diagnostic yield of PCNB. 
7--13
 Significant variability exists regarding 
which patients may benefit from PCNB, and standard surgical techniques have not been 
defined for PCNB. Several small studies have demonstrated lower or similar complication 
rates, but detailed procedural and post-operative outcomes are lacking.
5,7,8
 What remains 
unknown are the precise technical practices that may optimize the efficacy of PCNB required 
for current treatment protocols and for clinical trial enrollment. 
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To improve efficacy of PCNB, the Pediatric Surgical Oncology Research 
Collaborative (PSORC) conducted a multi-institutional, retrospective study to evaluate 
procedural details and outcomes of PCNB for neuroblastoma. Differences in technical 
practices and peri-operative outcomes were examined. These results set precedence for a 
collaborative multidisciplinary approach to establish technical standards for PCNB for 
pediatric solid tumors. 
Methods 
Twelve surgical centers in North America participated and contributed data to this 
study. All patients under the age of 18 with a new diagnosis of neuroblastoma between June 
1, 2014 and November 1, 2017 were included. Data extracted from chart review included 
demographic information, initial imaging modalities, characteristics of the mass (including 
size, position relative to critical anatomic structures, and evidence of necrosis on initial 
imaging), biopsy procedure type, technical details regarding the biopsy, complications from 
the biopsy procedure, diagnostic yield (including cytogenetic markers recommended by the 
Children’s Oncology Group [COG] protocols for pre-treatment risk stratification and clinical 
trial enrollment), clinical information detailing post-biopsy admission, and pain medication 
requirements. Data was de-identified and entered into a central secure database. 
Data was stratified according to type of initial surgical intervention: tumor excision, 
IB or PCNB. Patients who had tumor excision at diagnosis were not included in the 
comparative analysis. The primary outcome was success in establishing the diagnosis of 
neuroblastoma at the initial biopsy. Secondary outcomes included success in obtaining the 
critical cytogenetic markers (MYCN copy number, loss of heterozygosity (LOH), and tumor 
ploidy) needed for risk stratification; length of stay and NPO after biopsy; pain management 
profile (analgesics, opioid use, requirement of patient controlled analgesia [PCA]); 
transfusion requirements; need for repeat biopsy; and complications. Data was collected on 
 
This article is protected by copyright. All rights reserved. 
institutional site, surgical technique (number of core needle samples obtained, size/needle 
gauge of core needle biopsy, surgeon vs radiologist performing biopsy) and on pathologic 
characteristics (pathologist real-time tissue analysis, tumor size, and tumor necrosis). 
Study data was collected using the REDCap electronic data access tools, hosted at 
Cincinnati Children’s Hospital Medical Center, and converted to STATA for analysis.
14
 
Sample characteristics are reported as number of observations and percentages for categorical 
variables, and median and range for continuous variables. Comparisons between age, gender, 
adequacy of biopsy for diagnosis and cytogenetic analysis, complication rates, and need for 
post-operative analgesia were assessed by Chi-squared or Fisher’s Exact tests as appropriate. 
To account for the multi-center nature of the study design, mixed effect logistic regression 
analysis was used to assess the effects of tumor size, biopsy needle size, number of biopsies 
taken, presence of real-time pathologic review during the procedure, and necrosis on imaging 
on successful diagnosis and tumor characterization. All analyses were conducted in STATA 
v15.1, STATACorp, College Station, TX, (p value less than 0.05 considered statistically 
significant). 
Results 
A total of 243 children with newly diagnosed neuroblastoma were identified from 12 
institutions. Seventy-nine patients had tumor excision as the primary procedure and were 
therefore excluded from the comparative analysis. The remaining 164 were divided into two 
groups by initial biopsy type: 70 PCNB and 94 IB. (Figure 1) The only significant baseline 
demographic differences between the IB and PCNB groups was a higher proportion of male 
patients with IB. (Table 1) 
There was no difference between PCNB and IB in ability to determine the primary diagnosis 
of neuroblastoma (95.7% vs 98.9%, p = 0.314) or MYCN copy number (92.4% vs 97.8%, p = 
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0.111). IB was more successful at obtaining adequate samples for LOH (IB 91.8% vs PCNB 
60.8%, p < 0.05) and tumor ploidy analysis (IB 89.1% vs PCNB 57.8%, p < 0.05). (Table 2) 
Overall complication rate was low in both groups (PCNB 2.9% vs IB 3.33 %, p = 
0.624). Patients undergoing IB were more likely to require at least one blood transfusion 
during their admission (40.4% vs 15.7%, p = 0.001). Analgesia requirement, including opioid 
administration and the need for patient controlled analgesia were all lower in the PCNB 
group than the IB group. Patients undergoing PCNB were less likely to require hospital 
admission post-operatively than patients undergoing IB (80.0% vs 96.8%, p = 0.001). Length 
of stay and total days kept NPO did not differ between the two groups. (Table 3) 
Mixed effect logistic regression modeling was employed to evaluate for factors that 
contributed to higher diagnostic yield of the primary outcomes (primary diagnosis, MYCN 
copy number, LOH and tumor ploidy), while controlling for inter-institutional variability. 
There were no statistically significant relationships observed between core needle sizes, the 
numbers of core samples obtained, or usage of ultrasound guidance for biopsy and diagnostic 
yield. The impact of tumor size and tumor necrosis on imaging were also analyzed, and had 
no impact on diagnostic yield. 
Finally, we analyzed the effect that different personnel had on the diagnostic yield for 
patients undergoing PCNB. Of the seventy PCNB reviewed, 14 (20%) were performed by 
surgeons, while 56 (80%) were performed by interventional radiologists. There were no 
differences in diagnostic yield of any of the primary outcomes between surgeons and 
interventional radiologists. Surgeons were more likely than radiologists to use ultrasound 
guidance during percutaneous biopsy (100% vs 71.1%, p = 0.020). Masses biopsied by 
surgeons were larger than those biopsied by radiologists (median largest mass size 7.4 cm vs 
3.4 cm, p = 0.002), but did not have significantly more necrosis present on initial imaging 
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(28.6% biopsied by surgeons with necrosis, vs 10.5% by pathologists, p = 0.189). Six of the 
twelve centers had a pediatric pathologist present during PCNB to aid in ensuring adequacy 
of tissue specimen. Since diagnostic yield and MYCN copy number were already adequate, 
the presence of a pathologist did not alter these categories. While there were not effects on 
ability to obtain tumor ploidy (60.0% vs 55.8%, p = 0.791), the rate of adequacy for LOH 
was improved with a pathologist present to evaluate the gross specimen (92.8% vs 48.6%, p = 
0.008). (Table 4) 
Discussion 
The utilization of PCNB for diagnosis and pathologic characterization of neuroblastoma and 
other pediatric solid tumors has increased in recent years.
5,15
 Several reports have found 
similar efficacy in diagnosis rate between percutaneous and open biopsy methods, while 
others have reported decreased diagnostic yield with PCNB.
7,8,10,11
 The INRG classification 
system outlines pre-treatment risk groups to stratify patients based on probability of disease 
progression and recurrence. This classification system requires age, histologic factors, 
biologic and genetic characterization (MYCN amplification, DNA ploidy, and loss of 
heterozygosity at 11q).
1,16
 Small pilot studies have confirmed the ability of PCNB to obtain a 
diagnosis in neuroblastoma, but these have not uniformly included a robust evaluation of 
ability to obtain adequate tissue for complete genomic assessment. 
Our study compares the efficacy of PCNB and IB in both diagnosing neuroblastoma and 
obtaining complete genomic assessment of MYCN, LOH, and tumor ploidy. The ability of 
PCNB to determine the primary diagnosis of neuroblastoma and determine MYCN copy 
number was equivalent to IB. However, IB was superior to PCNB in determination of tumor 
ploidy status and LOH at 11q. This is an important issue to address as LOH and ploidy 
determinations are essential in accurate risk classification.
17
 Analysis of the technical aspects 
of PCNB was undertaken in order to identify practices that optimize tissue samples for 
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cytogenetic testing. Our results suggest that peri-procedural qualitative review of the gross 
specimen by a pediatric pathologist is associated with increased complete genetic assessment, 
including LOH. This is likely due to the ability of the pathologist to determine which core 
specimens contained viable appearing tissue versus necrotic cores. The current logistic 
regression analysis did not demonstrate significant association between number of cores 
obtained, size of percutaneous needle utilized, or tumor-specific features on imaging that 
increase diagnostic yield, although literature for other pediatric solid tumors have 
recommended the range of 10--20 cores be obtained at minimum.
18,19
 This is likely due to the 
relatively small sample sizes in subgroups within this analysis as a result of the many 
different technical steps, cores obtained, needle sizes, and equipment utilized both inter-
institutional and within the collaborative multicenter group. These variable results and 
previous retrospective studies set premise for larger prospective studies to further optimize 
successful PCNB techniques. Despite the lower number of PCNB patients with successful 
LOH (60.8%) and tumor ploidy assessment (57.8%), there was not a statistically significant 
increase in the number of patients requiring repeat biopsies (PCNB 7.1% vs IB 1.1%, p = 
0.085). (Table 3) This implies that the information received from PCNB is adequate for 
treatment decisions in select patients. 
This study and others have shown that PCNB is associated with lower morbidity than open 
biopsy. While complications in both groups were low, there was significantly less analgesia 
use in patients undergoing PCNB, as well as a lower incidence of blood transfusions. A large 
majority of patients in both groups were admitted post-operatively, and length of stay was 
significantly longer than would be expected from biopsy procedures alone. This is likely due 
to the frequent practice of admission, radiologic imaging for staging, multidisciplinary 
consultation, and induction chemotherapy immediately following biopsy, and it is therefore 
difficult to draw definitive conclusions regarding length of stay data. The majority of PCNB 
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were performed by interventional radiologists (80%), though some were performed by 
surgeons (20%). There were no significant differences in the diagnostic yield of biopsies 
obtained by either specialty in this study. Because both specialties perform PCNB depending 
on institution, a standardized technical approach could strengthen success of genetic analysis. 
The logistic regression in our analysis was not able to demonstrate differences in 
diagnostic ability with respect to cores obtained and needle size, and subgroup analysis was 
hindered by significant missing data in both groups -- 24% missing in the interventional 
radiologist performed group, and 43% in the surgeon-performed group. As a result, we felt 
that reporting the characteristics of the successful percutaneous biopsies in our group might 
aid clinicians in their decision making. Of the 52 patients who underwent percutaneous 
biopsy, 21 cases (40.3%) had tissue adequate for all primary diagnosis as well as genomic 
assessment of MYCN, LOH, and tumor ploidy. In this group, 38% underwent biopsy with an 
18 gauge need, 19% with a 16 gauge needle, and 14% with a 14 gauge needle or larger (29% 
had no needle size recorded). The median number of cores obtained in this group was 9, with 
an interquartile range of 6--30. 
This study has several limitations. Despite demographically similar groups, the retrospective 
nature of the study does not allow for randomized control groups and therefore we are unable 
to control for inherent bias. Additionally, data was not collected regarding rationale for the 
choice between percutaneous and open biopsy, and it may be that tumors which were smaller 
or more difficult to access percutaneously preferentially underwent open biopsy. Currently, 
there is no standard of care or protocol for PCNB technique, size of needle utilized, or 
number of cores obtained. There are also not current recommendations or requirements for 
pathologic review during the procedure for pretreatment risk stratification or clinical trial 
enrollment. While logistic regression attempted to evaluate trends in these areas, there was 
missing data regarding the sizes of needles (28.9% missing) and number of cores obtained 
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(9.6% missing), and this may confound the ability to detect a statistically significant 
difference. These limitations point to the need for a controlled, prospective, study for quality 
improvement. Finally, and perhaps importantly, we are not able to comment on the relative 
success of IB and PCNB in securing tissue for banking and experimental biologic research. 
Despite these limitations, this data demonstrates that there are significant benefits to PCNB in 
patients undergoing evaluation for neuroblastoma. PCNB was successful at obtaining 
histologic diagnosis and MYCN copy number. In select patients, this may be adequate to 
inform necessary pre-treatment decisions and spare patients the morbidity associated with 
open biopsy. PCNB was successful in obtaining the complete profile of genetic testing in 
about 60 percent and we hypothesize that this could be improved with vigilance, 
standardization of biopsy technique, and real-time pathology assessment of tissue. 
Conclusion 
PCNB for neuroblastoma is a feasible alternative to IB for select patients with neuroblastoma, 
but in current practice remains inadequate for obtaining important molecular data in a 
significant fraction of patients. Standardization of technical aspects that improve the yield of 
important cytogenetic information, including real time pathology review, represents an 
important opportunity to advance surgical care of children with neuroblastoma and other 
pediatric solid tumors. 
Conflicts of Interest Statement: 





This article is protected by copyright. All rights reserved. 
References 
1. Newman EA, Abdessalam S, Aldrink JH, et al. Update on neuroblastoma. J Pediatr 
Surg. 2019;54(3):383-389. doi:10.1016/j.jpedsurg.2018.09.004 
2. Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk 
Group (INRG) staging system: An INRG Task Force report. J Clin Oncol. 
2009;27(2):298-303. doi:10.1200/JCO.2008.16.6876 
3. Kim J, Sun Z, Adam MA, et al. Predictors of nodal metastasis in pediatric 
differentiated thyroid cancer. J Pediatr Surg. 2017;52(1):120-123. 
doi:10.1016/J.JPEDSURG.2016.10.033 
4. Pohlig F, Kirchhoff C, Lenze U, et al. Percutaneous core needle biopsy versus open 
biopsy in diagnostics of bone and soft tissue sarcoma: a retrospective study. Eur J Med 
Res. 2012;17(1):29. doi:10.1186/2047-783X-17-29 
5. Weldon CB, Madenci AL, Tiao GM, et al. Evaluation of the diagnostic biopsy 
approach for children with hepatoblastoma: A report from the Children’s Oncology 
Group AHEP 0731 Liver Tumor Committee. J Pediatr Surg. 2019;(xxxx). 
doi:10.1016/j.jpedsurg.2019.05.004 
6. Simon T, Matthay KK, Castel V, et al. The International Neuroblastoma Risk Group 
(INRG) Classification System: An INRG Task Force Report. J Clin Oncol. 
2008;27(2):289-297. doi:10.1200/jco.2008.16.6785 
7. Mullassery D, Sharma V, Salim A, et al. Open versus needle biopsy in diagnosing 
neuroblastoma. J Pediatr Surg. 2014;49(10):1505-1507. 
doi:10.1016/j.jpedsurg.2014.05.015 
8. Hassan SF, Mathur S, Magliaro TJ, et al. Needle core vs open biopsy for diagnosis of 
 
This article is protected by copyright. All rights reserved. 
intermediate- and high-risk neuroblastoma in children. J Pediatr Surg. 
2012;47(6):1261-1266. doi:10.1016/j.jpedsurg.2012.03.040 
9. Campagna G, Rosenfeld E, Foster J, et al. Evolving biopsy techniques for the 
diagnosis of neuroblastoma in children. J Pediatr Surg. 2018;53(11):2235-2239. 
doi:10.1016/j.jpedsurg.2018.04.012 
10. Gupta A, Kumar A, Walters S, Chait P, Irwin MS, Gerstle JT. Analysis of needle 
versus open biopsy for the diagnosis of advanced stage pediatric neuroblastoma. 
Pediatr Blood Cancer. 2006;47(7):875-879. doi:10.1002/pbc.20666 
11. Hoffer A, Chung T, Diller L, Kozakewich H, Fletcher A, Shamberger C. Percutaneous 
biopsy for prognostic testing of neuroblastoma. Radiology. 1996;200:213-216. 
doi:10.1148/radiology.200.1.8657913 
12. Metz T, Heider A, Vellody R, et al. Image-guided percutaneous core needle biopsy of 
soft-tissue masses in the pediatric population. Pediatr Radiol. 2016;46(8):1173-1178. 
doi:10.1007/s00247-016-3571-5 
13. Sklair-Levy M, Lebensart PD, Applbaum YH, et al. Percutaneous image-guided needle 
biopsy in children - Summary of our experience with 57 children. Pediatr Radiol. 
2001;31(10):732-736. doi:10.1007/s002470100533 
14. Harris PA, Thielke R, Gonzalez N, Conde JG, Taylor R, Payne J. Research electronic 
data capture (REDCap)---A metadata-driven methodology and workflow process for 
providing translational research informatics support. J Biomed Inform. 
2008;42(2):377-381. doi:10.1016/j.jbi.2008.08.010 
15. Campagna G, Rosenfeld E, Foster J, et al. Evolving biopsy techniques for the 
diagnosis of neuroblastoma in children. J Pediatr Surg. 2018. 
 
This article is protected by copyright. All rights reserved. 
doi:10.1016/j.jpedsurg.2018.04.012 
16. Riley RD, Heney D, Jones DR, et al. A systematic review of molecular and biological 
tumor markers in neuroblastoma. Clin Cancer Res. 2004;10(1 Pt 1):4-12. 
http://www.embase.com/search/results?subaction = viewrecord&from = export&id = 
L36005421%5Cnhttp://dx.doi.org/10.1016/S0959-8049(02)00500-
2%5Cnhttp://elvis.ubvu.vu.nl:9003/vulink?sid = EMBASE&issn = 09598049&id = 
doi:10.1016%2FS0959-8049%2802%2900500-2&atitle = A+syste. 
17. Schleiermacher G, Janoueix-Lerosey I, Ribeiro A, et al. Accumulation of segmental 
alterations determines progression in neuroblastoma. J Clin Oncol. 2010;28(19):3122-
3130. doi:10.1200/JCO.2009.26.7955 
18. Lim IIP, Bondoc AJ, Geller JI, Tiao GM. Hepatoblastoma---The Evolution of Biology, 
Surgery, and Transplantation. Children. 2018;6(1):1. doi:10.3390/children6010001 
19. López-Terrada D, Alaggio R, De Dávila MT, et al. Towards an international pediatric 
liver tumor consensus classification: Proceedings of the Los Angeles COG liver 
tumors symposium. Mod Pathol. 2014;27(3):472-491. doi:10.1038/modpathol.2013.80 
  
 
This article is protected by copyright. All rights reserved. 
Figure Legend: 
 
FIGURE 1: Details of patient selection and exclusion 
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TABLE 1: Demographics 
  Percutaneous Core Needle Biopsy 
n = 70 
Incisional Biopsy 
n = 94 
p-value 
Mean Age 2.81 yrs 2.58 yrs 0.639 
Gender (M/F) 32/38 60/34 0.021 
Race (n (%)) 
Caucasian 53 (75.7%) 74 (78.7%) 
0.675 
African American 4 (5.7%) 7 (7.5%) 
Hispanic 8 (11.4%) 10 (10.6%) 
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TABLE 2: Diagnostic yield of biopsies 
Sample Adequate for: 
(n, %) 
Percutaneous Core Needle Biopsy 
n = 70 
Incisional Biopsy 
n = 94 
p-value 
Primary Diagnosis 67 (95.7%) 93 (98.9%) 0.314 
MYCN copy number 61 (92.4%) 88 (97.8%) 0.111 
Loss of Heterozygosity 23 (56.1%) 40 (90.9%) < 0.05 
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TABLE 3: Secondary outcomes 
 Percutaneous Core Needle Biopsy 
n = 70 
Incisional Biopsy 
n = 94 
p-value 
Complications, n (%) 2 (2.90%) 3 (3.33%) 1.00 
Transfusion Required, n (%) 11 (15.7%) 38 (40.4%) 0.001 
Any Analgesia Required, n (%) 57 (86.4%) 77 (97.5%) 0.023 
Opiates Required, n (%) 43 (63.6%) 66 (83.5%) 0.006 
PCAa required, n (%) 7 (10.6%) 22 (27.9%) 0.010 
Repeat Biopsy Required, n (%) 5 (7.1%) 1 (1.1%) 0.085 
Admission Post-procedure, n (%) 56 (80.0%) 91 (96.8%) 0.001 
NPOb Duration (median days (IQRc)) 0 (0 – 0) 0 (0 – 1) 0.559 
Length of Stay (median days (IQRc)) 8 (3.5 – 22) 10 (6 – 19) 0.607 
a Patient Controlled Analgesia; b Nil per Os; c Interquartile Range 
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100% 94.6% 1.00 100% 93.5% 0.546 
Adequacy for 
MYCN copy, % 
100% 90.4% 0.576 100% 88.4% 0.158 
Adequacy for 
LOH, % 




71.4% 54.0% 0.360 60.0% 55.8% 0.791 
